Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...
May 22 (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results